Self-administration at home of prostaglandin for termination of early pregnancy

  • M. Bygdeman
  • N. J. Christensen
  • K. Gréen
  • O. Vesterqvist
Part of the Advances in Reproductive Health Care book series (ARHE, volume 4)


The possibility of using Prostaglandins for termination of early pregnancy was evaluated in 1971 (Karim, 1971). One of the objectives has been to develop a non-surgical, out-patient, possibly self-administered method as an alternative to vacuum aspiration in very early pregnancy (up to 49 days of amenorrhea).


Early Pregnancy Gynecological Examination Fertility Regulation Uterine Contractility Vaginal Suppository 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bygdeman, M. (1979). Menstrual regulation with Prostaglandins. In Karim, S. M. M. (ed.). Practical Applications of Prostaglandins and their Synthesis Inhibitors. pp. 267–282. ( Lancaster: MTP Press )Google Scholar
  2. Bygdeman, M., Bremme, K., Christensen, N., Lundström, V. and Gréen, K. (1980). A comparison of two stable Prostaglandin E analogues for termination of early pregnancy and for cervical dilatation. Contraception, 22, 471–483PubMedCrossRefGoogle Scholar
  3. Bygdeman, M., Christensen, N., Gréen, K. and Zheng, S. (1981). Self-administration of Prostaglandin for termination of early pregnancy. Contraception, 24, 45–52PubMedCrossRefGoogle Scholar
  4. Bygdeman, M., Christensen, N. J., Gréen, K., Zheng, S. and Lundström, V. (1983). Termination of early pregnancy. Future development. Acta Obstet. Gynecol. Scand., Suppl. 113, 125–129CrossRefGoogle Scholar
  5. Bygdeman, M., Gréen, K., Bergström, S., Bundy, G. and Kimball, F. (1979). New Prostaglandin E2 analogue for pregnancy termination. Lancet, 1, 1136PubMedCrossRefGoogle Scholar
  6. Gréen, K., Vesterqvist, O., Bygdeman, M., Christensen, N. J. and Bergström, S. (1982). Plasma levels of 9-deoxo-16,16-dimethyl-9-methylene PGE2 in connection with its development as an abortifacient. Prostaglandins, 24, 451–466PubMedCrossRefGoogle Scholar
  7. Karim, S. M. M. (1971). Once-a-month vaginal administration of Prostaglandins E2 and F for fertility control. Contraception, 3, 173–183CrossRefGoogle Scholar
  8. Karim, S. M. M., Rao, B., Ratnam, S. S., Prasad, R. N. V., Wong, Y. M. and Ilancheran, A. (1977). Termination of early pregnancy (menstrual induction) with 16-phenoxy-ω-tetrano PGE2 methyl sulfonylamide. Contraception, 16, 377–381PubMedCrossRefGoogle Scholar
  9. Kimball, F. A., Bundy, G. L., Robert, A. and Weeks, J. R. (1979). Synthesis and biological properties of 9-deoxo-16,16-dimethyl-9-methylene PGE2. Prostaglandins, 17, 657–666PubMedCrossRefGoogle Scholar
  10. Mocsary, P. and Csapo, A. I. (1975). Work in progress. Menstrual induction with PGF and PGE2. Prostaglandins, 10, 545–547PubMedGoogle Scholar
  11. Takagi, S., Sakata, H., Yoshida, T., Den, K., Fujii, K., Amemiya, H. and Tomita, M. (1978). Termination of early pregnancy by ONO-802 suppositories (16,16-dimethyl-trans-Δp2-PGE1 methyl ester). Prostaglandins, 15, 913–919PubMedCrossRefGoogle Scholar
  12. Tredway, D. R. and Mishell, D. R. (1973). Therapeutic abortion of early human gestation with vaginal suppositories of Prostaglandin F. Am. J. Obstet. Gynecol., 116, 795–798PubMedGoogle Scholar

Copyright information

© MTP Press Limited 1984

Authors and Affiliations

  • M. Bygdeman
  • N. J. Christensen
  • K. Gréen
  • O. Vesterqvist

There are no affiliations available

Personalised recommendations